In recent days, Boston Scientific announced a forthcoming CFO change, a Cambridge biotech undertook a 1-for-20 reverse stock ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

While President Trump and Elon Musk have cut spending on research and grants that fueled the life sciences and climate tech ...

A developer that specializes in office to lab conversions secured the largest life science lease of 2025 in Boston with a ...

As the months ticked by in his job search, Albert started to wonder if there was something wrong with him. He got advice on ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Some tariffs remain in place against key U.S. trading partners, but others have been postponed to give nations time to ...

Boston-based Odyssey Therapeutics Inc. filed ... have contributed to the pullback on IPOs in the last few years. Biotech companies have a high rate of failure, he said, and several years ago ...

Seattle, WA - NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its ...